[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Motol\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":219},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,75,103,135,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100630076","prevalence-of-symptomatic-gastroesophageal-reflux-disease-in-czech-children-czech-gerdkids-100630076",false,"NCT07482969","Prevalence of Symptomatic Gastroesophageal Reflux Disease in Czech Children (Czech GERDKids)","Prevalence of Symptomatic Gastroesophageal Reflux Disease in Children in the Czech Republic","Czech GERDKids","Inclusion Criteria:\n\n* age group of 8 - 9 years and 12 - 13 years\n* school attendance ability\n\nExclusion Criteria:\n\n* psychomotor impairment","ALL","8 Years","13 Years",{"count":21,"type":22},1000,"ESTIMATED","3 Months","OBSERVATIONAL","This study aims to determine the prevalence of symptomatic gastroesophageal reflux disease (GERD) in children aged 8-9 years and 12-13 years in the Czech Republic. Participants are recruited through schools and complete a web-based questionnaire assessing reflux-related symptoms. Children reporting pyrosis or regurgitation undergo a stepwise diagnostic evaluation that includes a standardized proton pump inhibitor (PPI) trial, upper endoscopy when indicated, and 24-hour pH-impedance monitoring for those with inconclusive findings. These procedures allow classification into confirmed GERD, reflux hypersensitivity, or functional pyrosis. All children undergoing diagnostic testing complete a validated quality-of-life questionnaire. The study will provide population-based prevalence estimates and evaluate symptom burden and potential risk factors associated with pediatric GERD.",[27],"Gastro Esophageal Reflux",[29,30,31,32],"Reflux disease","Children","Prevalence","Population","RECRUITING","2026-03-16",{"date":36,"type":37},"2026-03-19","ACTUAL",{"date":39,"type":37},"2025-12-20",{"date":41,"type":22},"2028-12-30",{"name":43,"class":44},"University Hospital, Motol","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100621917","time-in-range-vs-time-in-normal-glycemia-for-better-glycemic-control-100621917","NCT07376850","Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control","TANGO","Inclusion Criteria:\n\n* Diagnosis of T1D per ADA criteria\n* Age 5.0-17.99 at the start of study\n* CGM use \\>70% of the time during the month prior to enrollment\n* Maximum HbA1c of 86mmol\u002Fmol (10% in DCCT)\n\nExclusion Criteria:\n\n* No concurrent illnesses impacting glycemia\n* No treatments impacting glycemia\n* Severe hypoglycemia documented in the 60 day period leading up to patient recruitment\n* Current participation in any other interventional study\n* Any significant diseases \u002F conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise participant's safety\n* Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration","5 Years","18 Years",{"count":56,"type":22},120,"INTERVENTIONAL",[59],"NA","The TANGO study is a 12-month study involving 120 children and adolescents with Type 1 Diabetes (T1D) across the Czech Republic, Israel, and Poland who use automated insulin delivery (AID) systems.\n\nCurrently, the global standard for diabetes management is \"Time in Range\" (TIR), which aims to keep blood sugar levels between 70-180 mg\u002FdL. However, newer technologies like AID systems may now allow for a tighter, more physiological goal called \"Time in Normal Glycemia\" (TING), which targets a range of 70-140 mg\u002FdL.\n\nThis study will randomly assign participants to follow either the standard TIR target or the tighter TING target to see if the narrower range improves overall blood sugar control and HbA1c without increasing the risk of hypoglycemia, family stress, or daily treatment burden.\n\nBy comparing these two approaches, researchers hope to determine if clinical guidelines should be updated to reflect a more precise glucose target for children and adolescents worldwide",[62,63,64],"Diabetes","Diabetes (DM)","Diabetes Type 1","NOT_YET_RECRUITING","2026-01-21",{"date":68,"type":37},"2026-01-29",{"date":70,"type":22},"2026-01",{"date":72,"type":22},"2026-06",{"name":43,"class":44},3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100604409","pediatric-artificial-intelligence-for-retinopathy-screening-in-children-with-type-1-diabetes-100604409","NCT07149142","Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes","Feasibility and Effectiveness of Diabetic Retinopathy Screening Using Artificial Intelligence in Children With Type 1 Diabetes","PAIRS-T1D","Inclusion Criteria:\n\n* Type 1 diabetes diagnosed according to the ADA criteria\n* Age over 11.0 years or duration of diabetes over 2 years\n* Signed written informed consent by both the CwD and their parent\u002Fcaregiver\n\nExclusion Criteria:\n\n* Unwillingness to sign a written informed consent by both the CwD and their parent\u002Fcaregiver","11 Years","19 Years",{"count":86,"type":22},400,[59],"The proposed project is a clinical intervention trial testing the feasibility and effectiveness of diabetic retinopathy screening evaluated by artificial intelligence (AI) based software in children with type 1 diabetes (CwD). Another novel method, the confocal microscopy of the retina will be used to assess the early stages of diabetic neuropathy. In parallel, we aim to assess the prevalence of diabetic retinopathy and neuropathy in a well-controlled population of CwD at a tertiary diabetes care center.\n\nEach participant will undergo an examination of diabetic retinopathy using the non-mydriatic fundus camera. The resulting photography will be evaluated by AI driven software. The participant will then follow this examinaton with fundus ophtalmoscopy in arteficial mydriasis as a standard method of diabetic retinopathy assessment. Another method, the optic coherence tomography (OCT), which is considered as the most sensitive method for diabetic retinopathy assessment, will be performed after that. The results of these methods will be compared to assess the sensitivity of each. The examination-satisfaction questionnaire will be given to the participants.\n\nIn subjects over 18 years, a confocal microscopy of the retina examination will be performed to assess the status of the corneal sub-basal nerve plexus and the presence of diabetic neuropathy will be noted.\n\nThe prevalence of diabetic retinopathy and neuropathy in this group of children with diabetes will be assessed based on the results.",[90],"Type 1 Diabetes Mellitus",[92,93,94],"Diabetic Retinopathy","Diabetic Neuropathy","Artificial Intelligence","2025-09-10",{"date":97,"type":37},"2025-09-17",{"date":99,"type":22},"2026-01-01",{"date":101,"type":22},"2029-12-31",{"name":43,"class":44},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":111,"targetDuration":112,"studyType":24,"phases":4,"briefSummary":113,"conditions":114,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":45},"100600886","comprehensive-coronary-physiology-in-patients-with-angina-with-nonobstructive-coronary-arteries---czech-republic-100600886","NCT07103317","Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","Comprehensive COROnary PHYSiology Assessment in Patients With Angina With Nonobstructive Coronary Arteries - CZECH Republic (CoroPhys-CZECH)","CoroPhys-CZ","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements were performed",{"count":21,"type":22},"100 Years","Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of microcirculation and vasospastic disorders in causing angina. The microvascular bed is composed of vessels smaller than 400 microns in diameter. Their network is significantly larger than that of the epicardial vessels and serves essential functions, including regulating myocardial blood flow and cellular metabolism.\n\nAngina pectoris, a most frequent symptom of CAD or myocardial ischemia, was assumed to be caused by significant stenosis of the epicardial coronary artery. However, it was found that in over 50% of cases, there was no obstructive CAD, which is described as angina with no obstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary arteries (INOCA), according to the clinical setting.",[115,116,117,118,119,120,121],"ANOCA","ANOCA - Angina With Non-obstructive Coronary Arteries","MINOCA","Microvascular Dysfunction","Microvascular Angina","Vasospastic Angina","Acetylcholine",[115,123,117,124,119,120,125,126],"INOCA","Coronary Microvascular Dysfunction","Acetylcholine Testing","Coronary Termodilution","2025-08-01",{"date":129,"type":37},"2025-08-05",{"date":131,"type":37},"2023-04-20",{"date":133,"type":22},"2030-01-01",{"name":43,"class":44},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":45},"100582862","prospective-observational-pilot-study-of-lmwh-versus-ufh-as-ecmo-anticoagulation-in-lung-transplantation-100582862","NCT06868823","Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation: A Prospective, Observational, and Pilot Study","LUX-ET-LT","Inclusion Criteria:\n\n1. ⃣ Adults (≥18 years old).\n2. ⃣ Patients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support.\n3. ⃣ Planned perioperative anticoagulation with either UFH or LMWH, as determined by the attending anesthesiologist.\n4. ⃣ Ability to provide informed consent or consent provided by a legally authorized representative.\n\nExclusion Criteria:\n\n1. ⃣ Patients receiving ECMO as a bridge to lung transplantation.\n2. ⃣ Patients requiring postoperative continuation of ECMO.\n3. ⃣ Patients with perioperative blood loss ≥3,000 mL.\n4. ⃣ Patients undergoing lung re-transplantation.\n5. ⃣ History of severe coagulopathy or bleeding disorder.\n6. ⃣ Active use of antiplatelet or anticoagulant therapy (excluding study anticoagulants).\n7. ⃣ Known heparin-induced thrombocytopenia (HIT).\n8. ⃣ Severe liver dysfunction (Child-Pugh C) or end-stage renal disease requiring dialysis.\n9. ⃣ Pregnant or breastfeeding women.",{"count":144,"type":22},40,"The aim of this observational pilot study is to evaluate the effectiveness and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) as anticoagulation in perioperative ECMO during bilateral lung transplantation.\n\nThe main question this study seeks to answer is:\n\nDoes LMWH provide a safe and effective alternative to UFH for ECMO anticoagulation in lung transplantation, with reduced bleeding and thrombotic complications?\n\nPatients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support will be assigned to one of two anticoagulation strategies:\n\nUFH group: Standard UFH anticoagulation monitored using ROTEM. LMWH group: Enoxaparin-based anticoagulation monitored using ROTEM. The study will assess perioperative blood loss, hemoglobin levels, transfusion needs, and thrombotic events. Additional analyses will include coagulation profile assessments using point-of-care (POC) tests, thrombin generation test (TGT), and laboratory coagulation parameters.",[147,148,149],"Lung Transplantation","Extracorporeal Membrane Oxygenation (ECMO)","Anticoagulants and Bleeding Disorders",[147,148,151,152,153,154,155,156,157,158],"Anticoagulation","Low-Molecular-Weight Heparin (LMWH)","Unfractionated Heparin (UFH)","Thrombosis Prevention","Bleeding Complications","Coagulation Management in Surgery","Hemorrhagic and Thrombotic Events","Perioperative Hemostasis","2025-06-09",{"date":161,"type":37},"2025-06-10",{"date":163,"type":37},"2025-05-01",{"date":165,"type":22},"2025-12-31",{"name":43,"class":44},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":57,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":45},"100554341","geranylgeraniol-supplementation-in-patients-with-mevalonate-kinase-deficiency-100554341","NCT06497829","Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency","Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency, MVK Deficiency (hyperIgD Syndrome)","Inclusion Criteria:\n\n* Patients older than 12 years with genetically confirmed MVK deficiency\n* Overall good clinical status apart from the clinical presentation of the MVK deficiency\n* Normal liver tests\n* Compliance with the study protocol\n\nExclusion Criteria:\n\n• Children below 12 years",true,"12 Years",{"count":177,"type":22},6,[59],"Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway. The subsequent lack of isoprenoids with antiinflammatory properties might contribute to the autoinflammatory nature of the disease.\n\nA pilot study aims to verify the safety and efficacy of the dietary supplement Geranylgeraniol, aiming at a mitigation of isoprenoids deficiency caused by the above-mentioned block in the MVK pathway.",[181],"Mevalonate Kinase Deficiency",[183,184,185,186],"immunoglobulin D","mevalonate kinase","isoprenoids","geranylgeraniol","2024-07-09",{"date":189,"type":37},"2024-07-12",{"date":191,"type":37},"2022-01-25",{"date":165,"type":22},{"name":43,"class":44},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100545472","glycemic-excursions-in-patients-with-type-1-diabetes-mellitus-using-closed-loop-systems-100545472","NCT06382350","Glycemic Excursions in Patients With Type 1 Diabetes Mellitus Using Closed-loop Systems","Glycemic Excursions in Patients With Type 1 Diabetes Mellitus Using Closed-loop Systems (Insulin Pump and Continuous Glucose Monitor) Versus Conventional Treatment in Different Life Situations - an Observational Multicenter Study","SAFEDRIVE","Inclusion criteria\n\nStudy group:\n\n* type 1 diabetes\n* patients aged ≥18 year\n* diabetes duration ≥3 years\n* regularly driving (non-professional drivers only)\n* treated with insulin pump MiniMed 780 G for at least 6 months with closed-loop setting treatment\n* willing to fill in the study questionnaires\n* signed patient's informed consent form\n\nControl group:\n\n* type 1 diabetes\n* patients aged ≥18 years\n* diabetes duration ≥3 years\n* regularly driving (non-professional drivers only)\n* treatment with multiple daily injections (MDI) of insulin therapy and the use of CGM for at least 6 months\n* willing to fill in the study questionnaires\n* signed patient's informed consent form\n\nExclusion Criteria (for study and control groups)\n\n* professional drivers\n* pregnancy\n* inability to be present at the follow-up visit\n* inability to complete the study questionnaires\n* participation in another clinical study within the last 3 months",{"count":56,"type":22},"The study aims to compare glycemic excursions during several life situations (such as periods of driving, periods of night sleep, periods of occupation, periods of physical activity, and periods of stress) in patients with type 1 diabetes treated with closed-loop system and multiple daily insulin dose therapy",[90,205,206],"Type 1 Diabetes Mellitus With Hypoglycemia","Drive",[208,209,210],"Type 1 diabetes mellitus","Driving","Closed-loop system","2024-06-02",{"date":213,"type":37},"2024-06-04",{"date":215,"type":37},"2024-05-29",{"date":217,"type":22},"2026-05",{"name":43,"class":44},""]